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Abstract
Background: MicroRNAs (miRNAs) have been proved to play an important role in various cellular processes and function as
tumor suppressors or oncogenes in cancers including leukemia. The identification of a large number of novel miRNAs and
other small regulatory RNAs will provide valuable insights into the roles they play in tumorgenesis.
Methodology/Principal Findings: To gain further understanding of the role of miRNAs relevant to acute lymphoblastic
leukemia (ALL), we employed the sequencing-by-synthesis (SBS) strategy to sequence small RNA libraries prepared from ALL
patients and normal donors. In total we identified 159 novel miRNAs and 116 novel miRNA*s from both libraries. Among the
159 novel miRNAs, 42 were identified with high stringency in our data set. Furthermore, we demonstrated the different
expression patterns of 20 newly identified and several known miRNAs between ALL patients and normal donors, suggesting
these miRNAs may be associated with ALL and could constitute an ALL-specific miRNA signature. Interestingly, GO
‘‘biological process’’ classifications revealed that a set of significantly abnormally expressed miRNAs are associated with
disease relapse, which implies that these dysregulated miRNAs might promote the progression of ALL by regulating genes
involved in the pathway of the disease development.
Conclusion/Significance: The study presents a comprehensive picture of the expression of small RNAs in human acute
lymphoblastic leukemia and highlights novel and known miRNAs differentially expressed between ALL patients and normal
donors. To our knowledge, this is the first study to look at genome-wide known and novel miRNA expression patterns in in
human acute lymphoblastic leukemia. Our data revealed that these deregulated miRNAs may be associated with ALL or the
onset of relapse.
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Introduction
MicroRNAs (miRNAs) are a class of endogenous noncoding
RNAs, between 19 to 25 nucleotides in size, which can regulate
gene expression at either the transcriptional or post-transcriptional
level [1]. Studies have shown that miRNAs play an important role
in development and various cellular processes, such as differen-
tiation, growth, and death [2]. A connection between miRNAs
and cancers has also been elucidated [3]. It has been shown that
about 50% of annotated human miRNAs are located at fragile
sites and genomic regions involved in cancers [4]. Other data
indicates that miRNAs function as both tumor suppressors and
oncogenes in tumorigenesis and cancer-specific miRNA expression
signatures have been identified in many cancers [4–7]. Identifi-
cation of a large number of novel miRNAs and other small
regulatory RNAs is critical to provide valuable insights into the
role these may play in tumorgenesis.
Recently, the sequencing-based method has been widely applied
for identifying and profiling novel miRNAs candidates. Studies on
novel miRNAs based on the sequencing method have been
reported in chicken, human embryonic stem cells, solid cancers,
etc. [8–14]. In leukemia, Marton et al. [15] used a cloning-based
sequencing approach to study small RNAs from chronic
lymphocytic leukemia (CLL) patients and five novel miRNA
candidates were identified, which could be relevant in CLL
pathogenesis. Another study examined miRNA expression profiles
and isolated many novel miRNAs candidates from leukemia cells
mainly present in acute myeloid leukemia (AML) by means of
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e6849miRNA amplification and sequencing [16]. Their results suggest
that there are still many novel miRNAs existing in leukemia cells.
Recently, the Illumina massively parallel sequencing platform was
used to carry out an in-depth analysis of the miRNA transcriptome
in a murine AML leukemia progression model and 55 novel
miRNAs were identified, some of which could be relevant to the
pathogenesis of AML [17], indicating that the high-throughput
sequencing method can be used as a new and powerful tool to
identify unannotated novel miRNA candidates which are lowly
abundant or nonconserved but relevant to the diseased state.
Acute lymphoblastic leukemia (ALL) is a malignant disorder of
lymphoid progenitor cells and characterized by chromosomal
abnormalities, which occurs at all ages but with peak prevalence
between the ages of 2 and 5 years [18]. With modern treatment
strategies using risk-adapted combination chemotherapy, the cure
rates of childhood ALL are almost 80% [19]. However, 20–30%
of children still relapse and conventional intensive chemotherapy
can only cure up to 30% of children who have relapsed [20–21].
As treatment of relapsed disease remains a challenging, the
accurate assignment of individual patients to risk groups is a
critical issue for optimal outcome[20,22,23]. Although microRNA
expression signatures associated with cytogenetics and the clinical
outcome of ALL have been reported [24–27], these efforts are
limited as they are mainly restricted to the detection and profiling
of previously identified miRNA sequences.
To gain a more complete and unbiased view of the small RNA
transcriptome and further understand the role of miRNAs relevant
to ALL, we employed a sequencing-by-synthesis (SBS) strategy to
globally study small RNAs, especially miRNAs that have thus far
been proven difficult to find using traditional cloning and in silico
predictions. We present a comprehensive picture of the expression
of small RNAs and have identified 159 novel miRNAs in total.
Notably, the unique expression patterns in ALL patients and GO
analysis suggest a set of miRNAs may be associated with disease
relapse, which provides valuable insight into the pathogenesis of
ALL relapse.
Results
Annotation of small RNAs and identification of novel
miRNA genes from patient group and normal donor
To discover additional miRNAs that have escaped detection in
previous studies associated with ALL [24–27], we employed SBS
strategy to sequence two small RNA libraries of pooled bone
marrows from a patient group (P) and a normal donor group (N).
This yielded 4,418,887 (P) and 4,361,324 (N) reads, respectively.
After computer filtering to remove ambiguous reads, 831,728 (P)
and 1,993,962 (N) sequence reads were obtained corresponding to
60,460 (P) and 113,414 (N) unique reads (18 nt,30 nt). Unique
sequences were mapped to the human genome (Mar. 2006,
version hg18, NCBI Build 36.1) using MegaBLAST [28] (version
2.2.18), and those with perfect matches across their entire length
were retained. Consequently, a total of 15,537 and 23,859 unique
sequences represented by 608,358 (P) and 1,327,742 (N) reads
were perfectly matched to 3,905,630 and 4,119,366 genome loci,
respectively. The schematic representation of small RNA library
sequencing and subsequent bioinformatic analysis is shown in
Fig. 1. These sequences were annotated based on their overlap
with publicly available genome annotations (Table S1) and a
total of 472 known miRNAs were identified with a greater total
number of miRNAs expressed in the normal donor group than in
the patient group (Fig. 2A). By analyzing the precursor sequence
of miRNAs, we identified a total of 74 novel miRNA*(star)s
(Table S2) in both groups. Mature miRNAs are processed from
the stem of a hairpin precursor, and the miRNA*(star) sequence
corresponds to the section of this hairpin that remains comple-
mentary to the mature form with approximately 2-nucleotide 39
overhangs [29,30]. Among them, we found that some miRNA*s
such as hsa-miR-766* were significantly up-regulated in the
patient group, whilst some miRNA*s such as hsa-miR-1307* were
significantly down-regulated in the patient group with fold changes
Figure 1. Schematic representation of small RNA library
sequencing and subsequent bioinformatic analysis.
doi:10.1371/journal.pone.0006849.g001
Figure 2. Venn diagram of the known miRNAs and novel
miRNA*(star)s of the known miRNAs identified from the
control group and the ALL patient group. (A) Known miRNAs
unique in each group and shared by both. (B) MiRNA*s of known
miRNAs unique in each group and shared by both.
doi:10.1371/journal.pone.0006849.g002
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involved in the progression of ALL.
To identify novel miRNAs among the unclassified sequences in
our libraries, we removed all known miRNAs, other small RNAs
and genomic repeats. A total of 12,798 unique sequences
(corresponding to 55,128 reads) in the normal donor library and
7,356 (corresponding to 29,599 reads) in the ALL library were
unannotated. We next evaluated reads that fell within potential
miRNA-like hairpins considering the criteria: 1) z-score less than
23.0, this discriminate significantly miRNAs from other struc-
tured RNAs [31–33]. 2) A total number of reads from two libraries
at least three reads in harpins or 3) the presence of reads
corresponding to the predicted miRNA* species [13,34]. Novel
candidate miRNAs had to satisfy criteria 1, and one of criteria 2
and 3. One hundred and fifty nine novel miRNAs(Fig. S1) and
116 novel miRNA*s were identified from the two libraries. As
described by Ruby et al. [13], the observation of both a candidate
miRNA and a corresponding candidate miRNA* in a set of reads
provides particularly compelling evidence for Dicer-like processing
from an RNA hairpin. Therefore, 42 out of 159 novel candidate
miRNAs met the criteria. Among the 42 novel miRNAs meeting
the highly stringenct criteria, 22 and 5 novel miRNAs are unique
in normal donor and ALL patient groups, respectively. The other
15 novel miRNAs are shared by both groups (Table 1, Fig. 2B).
Differentially expressed patterns of known and novel
miRNAs between control and patient group
Using this sequencing platform, we performed a systematic
miRNA expression profiling analysis of patient samples. A total of
847 miRNAs including miRNA*s (miRBase 11.0) were evaluated
and the relative expression of each miRNA between control and
patient were examined, 472 of which were detected in control or
patient samples. Only 77 miRNAs were up-regulated and 67
miRNAs were down-regulated in the patient group when
compared to the control group with fold changes .2.0 and a P-
value of ,0.001 (Table S3). The top 40 miRNAs differentially
expressed in patient samples with counts.200 and fold chang-
es.2.0 and P-value of ,0.001 are listed in Table S4. Of these,
miR-9*, miR-9, miR-181a and miR-128 exhibited a significantly
high abundance, whilst miR-582-5p, miR-223, miR-143, miR-126
etc. displayed the most significantly reduction in the patient group
(Fig. 3). We further performed qRT-PCR to examine the
expression levels of randomly selected miR-223. Results showed
that expression of miR-223 is significantly reduced over 2 fold
compared to control in 85% (17/20) of ALL patients (part of data
is shown in Fig. 4A). Additionally, we have found that some data
in this study are consistent with previous findings reported by Mi
et al [26] using microarray analysis. For example, miR-128, miR-
130b and miR-210 were up-regulated and miR-424, miR-223,
miR-23a, miR-27a were down-regulated in the patient group,
indicating that there is a concordance between the findings despite
using completely different miRNA expression analysis platforms,
which suggests that these novel techniques are robust.
To investigate the potential disease relevance of novel miRNAs,
we compared different expression of novel miRNAs in the patient
group with normal control. Only 20 out of 201 newly identified
miRNAs/miRNA*s exhibited significantly differential expression
between the two groups with fold changes .2.0 and a P-value of
,0.001. Among them, 6 miRNAs exhibited increased expression
and 14 other miRNAs showed reduced expression (Table 2). The
six most highly expressed miRNAs are miR-1943, miR-1841,
miR-1931, miR-1987, miR-1890, miR-1902 and the most lowly
expressed miRNAs are miR-1893, miR-1971*, miR-1834, miR-
1842*, miR-1842. We further used qRT-PCR to examine
expression levels of three randomly selected highly down-regulated
novel miRNA candidates: miR-1842, miR-1859* and miR-1852
in 20 ALL patients’ and three normal donors’ samples. Results
showed that all these miRNAs can be detected in all clinical
samples. Interestingly, we found that miR-1842 (16/20), miR-
1852 (13/20) and miR-1859* (14/20) had significantly reduced
expressions in most ALL patients compared to normal donors.
This is consistent with our results derived using Solexa sequencing
technology and suggests that these novel miRNAs may have
functional relevance in the pathogenesis of ALL (part of data is
shown in Fig. 4B–D).
Gene Ontology analysis reveals a set of abnormally
expressed miRNAs involved in the pathway of nervous
system development
The targets of the 171 known and novel miRNAs displaying
significantly different expression between the normal donors and
patient group (fold changes .2.0 and a p-value of ,0.001, Table
S5) [35–36] were predicted by miRNAs TargetScan to further
elucidate their pathological relevance. By examining the signifi-
cant GO ‘‘biological process’’ classifications that are over-
represented among these likely targets genes of the differentially
expressed miRNAs, we analyzed the functional annotation for
predicted target sets expected to shed light on the specific function
of miRNAs significant to ALL biology. Clustering of over-
represented GO classes in predicted targets of up-regulated and
down-regualted miRNAs in ALL showed that the most significant
GO terms were genes involved in cell adhesion, hemophilic cell
adhesion, transcription and regulation of transcription (Fig. 5).
Interestingly, another cluster of highly significant GO terms was
associated with nervous system development, i.e. neuronal cell
differentiation, which might be associated with the pathogenesis of
ALL with subsequent central nervous system (CNS) relapse,
suggesting that a set of significantly dysregulated miRNAs might
promote the progression of CNS relapse in ALL by regulating
genes in the pathway of nervous system development.
Discussion
To gain insight into the roles of miRNAs in the progression of
ALL, we have employed SBS strategy to globally study small
RNAs, especially miRNA expression profiles in ALL patients and
their normal counterparts. Our results revealed that there are a
large number of miRNAs deregulated in ALL patients, of which
some known and novel miRNAs may be involved in the
progression of ALL or relapse.
Although 678 human miRNA sequences have been cataloged
(miRBase, release 11.0, 2008) and identified by either cloning or
computational prediction, the identification of unannotated and
cancer-specific novel miRNAs candidates which are of low
abundance or nonconserved is important to comprehensively
understand the pathogenesis of leukemia and explore new
therapeutic strategies. In this study, we identified 275 novel
miRNAs/miRNA*s. Amongst these were 20 newly identified
miRNAs, including 6 up-regulated and 14 down-regulated
miRNAs exhibiting significantly differential expression in the
patient group with fold changes .2.0 and a p-value of ,0.001. We
further used qRT-PCR to validate the expression of miR-1842
and miR-1852 and the results revealed that 80% (16/20) and 65%
(13/20) of ALL patients had significantly down-regulated miR-
1842 and miR-1852, respectively. This indicates that these novel
miRNAs may have functional relevance in the pathogenesis of
ALL. Schotte et al. [24] identified 8 new miRNA genes from
childhood ALL patients using a cloning strategy. However, these 8
Novel MicroRNA in Human ALL
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overlapped with tRNA, rRNA, AluSx, HY3 RNA, HY5 RNA,or
due to poor secondary structure.
MiRNA*, also called passenger strand, has been considered as
an inactive strand and prone to be degradation [37]. However,
recent studies found that both pre-miRNA arms can functionally
suppress the expression of their target genes and the miRNA*
strand has inhibitory activity [30,38–39]. By analyzing the
precursor sequence of miRNAs, we identified a total of 116
novel miRNA*s, including 74 miRNA*s of known miRNAs and
42 miRNA*s of novel miRNAs and found that some miRNA*s
were significantly dysregulatedi nA L Lp a t i e n tg r o u pw i t hf o l d
changes .2.0 and a p-value of ,0.001. For example, we
elucidated that miR-1859* was significantly down-regulated
Table 1. 42 novel candidate miRNAs identified from control and patient group.
MiRNA Sequence MiRNA Reads C group MiRNA Reads P group MiRNA* Reads C group MiRNA* Reads P group
hsa-miR-1832 TCCACATGTAAAAAAATGAATC 7 0 3 4
hsa-miR-1836 AAAAGTTATTGTGGTTTTTGCT 8 0 3 2
hsa-miR-1842 AAAACCGTCTAGTTACAGTTGT 355 4 44 0
hsa-miR-1845 ACATGGAGTTCAGGTGAGGATT 1 0 0 1
hsa-miR-1851 AGACCCATTGAGGAGAAGGTTC 4 0 1 0
hsa-miR-1852 CCTGCAACTTTGCCTGATCAGA 66 2 40 1
hsa-miR-1855 AAAAGTAATTGTTGTTCTTGCC 0 3 0 1
hsa-miR-1859 ATCCCCAGATACAATGGACAAT 103 14 121 14
hsa-miR-1866 CATCAGAATTCATGGAGGCTAGA 30 2 6 0
hsa-miR-1872 TCTCAGTAAGTGGCACTCTGTC 0 1 0 1
hsa-miR-1876 AGCTTTTGGGAATTCAGGTAG 6 1 1 1
hsa-miR-1886 GCAAAGACCACGATTACTTTT 2 0 2 0
hsa-miR-1889 TCCAGTACATATAAAGAGACTT 2 0 1 0
hsa-miR-1896 TTCAGTGTAACTCAACATTTGA 3 0 4 0
hsa-miR-1901 AATTACAGATTGTCTCAGAGAA 175 51 21 6
hsa-miR-1906 TGAGGAGATCGTCGAGGTTGG 4 0 1 0
hsa-miR-1909 TTAGCCAATTGTCCATCTTTAG 3 1 3 0
hsa-miR-1911 CACTTGTAATGGAGAACACT 2 0 0 1
hsa-miR-1915 CAGACAGCTTGCACTGACT 1 0 1 0
hsa-miR-1916 AAAATCCTTTTTGTTTTTCCAG 3 0 1 0
hsa-miR-1917 CACAAGATGCCTAGTTAAATTT 1 0 1 1
hsa-miR-1923 AAATACCACAGTTACTTTTGCA 2 0 0 1
hsa-miR-1926 TATCGTGCATATATCTACCACAT 2 0 1 3
hsa-miR-1929 TTAATATGTACTGACAAAGCGT 4 0 4 0
hsa-miR-1930 CCTCCCACTGCAGAGCCTGGGGA 1 0 0 1
hsa-miR-1932 TTGTGAAGAAAGAAATTCTTA 12 0 4 1
hsa-miR-1940 CCAGAGAAGGCTGCTCCTCACCA 1 0 0 1
hsa-miR-1941 AAGAGTTACTAGAACTATT 2 0 2 0
hsa-miR-1942 AATTTATTCTTGGTAGGTTGT 1 0 2 0
hsa-miR-1945 TGGGACTGATCTTGATGTCT 5 9 0 1
hsa-miR-1946 TTTAGTACCTATAATGTGCTAG 2 0 0 1
hsa-miR-1947 TGTTGTACTTTTTTTTTTGTTC 120 12 23 2
hsa-miR-1953 GCCCTGCCTGTTTTCTCCTTTG 1 1 1 1
hsa-miR-1955 AGCAATACTGTTACCTGAAAT 2 4 1 0
hsa-miR-1962 AGAAGGGGTGAAATTTAAACGT 7 3 1 0
hsa-miR-1963 AGAAGGGGTGAAATTTAAACGT 7 3 1 0
hsa-miR-1964 AGAAGGGGTGAAATTTAAACGT 7 3 1 0
hsa-miR-1967 TAGCTGTAGCTTTAGCAGAGC 0 1 0 1
hsa-miR-1971 TAGCCTTCAGATCTTGGTGTTT 125 11 34 0
hsa-miR-1972 TGAGACAGGCTTATGCTGCTA 0 4 0 1
hsa-miR-1975 CAAAAGTAATTGTGGTTTTTGTT 0 1 0 1
hsa-miR-1984 AATCTGAGAAGGCGCACAAGGTT 2 0 1 0
doi:10.1371/journal.pone.0006849.t001
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be involved in the progression of ALL. Interestingly, BCL-2,a n
anti-apoptotic gene, was predicted to be one of the conserved
targets of miR-1859* based on the targetscan prediction
algorithm (www.targetscan. com) for the seed region
(TTGTCCT). Overexpression of the BCL-2 protein has been
frequently observed in many cancers including ALL [40–41].
Recently, it has been demonstrated that ALL cells are dependent
on BCL-2, suggesting BCL-2 might be a more clinically
significant parameter in ALL [42]. Therefore it is likely that
down-regulated miRNA-1859* contributes to the progression of
ALL by targeting the anti-apoptotic gene BCL-2.
In order to highlight the genes that are likely to be the targets of
the known and novel miRNAs and to analyse their relevance to
the pathogenesis of ALL, we also examined the significant GO
‘‘biological process’’ classifications that are over-represented
among these targets genes of the 171 known and novel
differentially expressed miRNAs. This analysis revealed that the
most significant GO terms were genes involved in cell adhesion,
hemophilic cell adhesion, transcription and regulation of tran-
scriptio. Interestingly, target prediction of the miRNA pattern
revealed that some abnormally expressed miRNAs may be
involved in the pathway of nervous system development, i.e.
neuronal cell differentiation. Notably, we found that the nervous
system development related gene Sox11 was the target of miR-
1986. Sox11 is important for neurogenesis, neural cell survival and
neurite outgrowth [43–44], which implies that miRNAs might be
associated with the pathogenesis of ALL with subsequent central
nervous system (CNS) relapse. CNS relapse is the main source of
extramedullary relapse in ALL, and has accounted for 30–40% of
initial relapses in some clinical trials [18,41]. Further study of the
differential expression patterns of known and novel miRNAs,
together with the clinic follow up information, may reveal a
miRNA signature as a biomarker for detection of early CNS
relapse in pediatric ALL patients.
In conclusion, we present a comprehensive picture of the
expression of small RNAs and in total have identified 159 novel
miRNAs and 116 novel miRNA*s using an SBS strategy and
computational analysis. To our knowledge, this is the first study to
look at known and novel miRNA expression pattern in human
ALL. Notably, we confirmed the expressions of some novel
miRNAs and demonstrated that miRNAs are different between
ALL patients and normal donors. Our data suggests these
deregulated known and novel miRNAs may be associated with
ALL or the onset of CNS relapses due to ALL.
Methods
Clinical samples and Ethics Statement
A total of 32 bone marrow samples including 27 ALL untreated
pediatric patients and 5 normal donors were enrolled from the
First and Second Affiliated Hospital of Sun Yat-sen University in
this study. Among them, 3 ALL patients’ and 2 normal donors’
(control group) bone marrows were pooled respectively for small
RNA library construction for Solexa sequencing. Another 24 ALL
patients and 3 normal donors were used as a validation set to
confirm the miRNA differential expression by qRT-PCR. Bone
marrow samples were taken by bone marrow puncture at
diagnosis. Written informed consent for biological studies was
obtained from all patients analyzed. The study was approved by
the Ethics Committee of the affiliated hospitals of Sun Yat-sen
University.
Total RNA isolation, small RNA library preparation, and
nucleotide sequencing
Total RNA was isolated with Trizol (Invitrogen, Carlsbad, CA)
according to the instructions of the manufacturer. Small RNA
library preparation and sequencing were performed with Solexa
sequencing Technology (BGI, Shenzhen, China). Briefly, total
RNA was size fractionated on a 15% tris-borate-EDTA (TBE)
urea polyacrylamide gel and a 15–30 nt fraction was excised, using
10 bp ladder (Invitrogen) as marker. RNA was eluted from the
polyacrylamide gel slice by Spin-X filter (Fisher) and precipitated
by addition of 750 mL of 100% ethanol and 3 mL of glycogen and
incubating at 280uC for 30 minutes. After washing with 75%
ethanol, the RNA pellet was dissolved in DEPC-treated water.
The RNA was dephosphorylated by alkaline phosphatase and
recovered by ethanol precipitation. The small RNAs pools were
Figure 3. Differential expression of miRNAs in ALL patients. Box plots (median and interquartile range) show the distribution of fold change
of expression in ALL patients compared with normal donor samples.
doi:10.1371/journal.pone.0006849.g003
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GUUCUACAGUCCGACGAUC-39) with T4 RNA ligase (Pro-
mega). The ligated RNA was size fractionated on a 15% TBE urea
polyacrylamide gel, and a 40–60 nt fraction was excised. The
RNA was eluted, precipitated and resuspended as described
above. The 39RNA adapter (59-pUCGUAUGCCGUCUUCUG-
CUUGidT-39; p, phosphate; idT, inverted deoxythymidine) was
subsequently ligated to the precipitated RNA with T4 RNA ligase.
Ligated RNA was size fractionated on a 10% TBE urea
polyacrylamide gel, and the 70–90 nt fraction was excised. The
RNA was eluted from the polyacrylamide gel and precipitated and
resuspended in DEPC water. Then, reverse transcription reaction
was preformed after ligation with adapters using Superscript II
reverse transcriptase (Invitrogen) and Solexa’s small RNA RT-
Primer (59-CAAGCAGAAGACGGCATACGA-39) and followed
byPCRamplificationwithHotstartPhusionDNAPolymerase(NEB)
in 15 cycles using Solexa’s small RNA primer set (59-CAAGCA-
GAAGACGGCATACGA-39;5 9-AATGATACGGCGACCACC-
GACAGGTTCAGAGTTCTACAGTCCGA-39). PCR products
were purified on a 6% TBE polyacrylamide gel using a 25 bp
DNA marker (Invitrogen). An approximately 92 bp fraction was
excised, eluted and precipitated by ethanol. The pellet was dissolved
in EB buffer and diluted for sequencing on the Solexa Genome
Sequencer.
Initial processing of reads
Low quality reads were filtered and 39 adaptor sequence
trimmed. Adaptor contaminants were cleaned up and 18–30 nt
reads collected. The remaining reads were discarded. We
calculated sequencing frequency of each unique small RNA
sequence, the number of reads for each sequence reflecting relative
abundance. Each unique sequence was aligned to the human
reference genome (Version hg18, Mar. 2006, NCBI Build 36.1,
obtained from the UCSC Genome Browser download page) using
MegaBLAST [28] with the following options: -W 15 –F F. Only
perfect matches over their entire length were set aside. All mapped
sequences were also searched against the human miRNA, tRNA,
rRNA, snoRNA, snRNA, scRNA or refGene (exonic) (miRBase
11.0, UCSC annotation). These annotated RNAs were removed.
To avoid repeat associated sequences, reads with more than five
total matching positions in the genome were discarded. We
aligned known mature miRNA sequence to the human genome
and 97% known mature sequences are less than five positions
(Fig. S2). The genomic loci corresponding to sequences remaining
Figure 4. The expressions of four miRNA were validated in the patient group compared with the control group using qRT-PCR.
doi:10.1371/journal.pone.0006849.g004
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secondary structure that is characteristic of miRNA precursors.
Each miRNA tally from each library was normalized to the total
number of miRNA hairpin-matching reads for that library, and
those normalized tallies were used for relative expression analysis.
Known miRNAs expression analysis
Relative expression analysis was sought to determine the
expression preferences of individual miRNAs between these two
libraries. The number of reads matching a particular mature
miRNA was calculated, but only sequence matches that
overlapped at least 10 nt with the dominantly abundant mature
miRNA sequence contributed to the miRNA tally. The Audic and
Claverie test was used to establish the statistical significance of the
difference in read frequencies for predicting differential miRNA
expression based on the comparison of tag counts generated from
digital expression analyses [46]. The program winflat (http://
www.igs.cnrs-mrs.fr/SpipInternet/IMG/tgz/winflat.tgz) was used
to compute the probability of differential miRNA. A p-value of
#0.001 was chosen as a threshold for determining significant
differential miRNA expression.
Novel miRNAs prediction
Sequences from 100 nucleotide (nt) upstream to 100 nt
downstream of the remaining aligned reads were extracted from
the human genome. Potential miRNA stem loops were located by
sliding a 100 nt window advancing by 10-nt increments along the
strand of read sequences and folding the window with the
secondary structure prediction program RNAfold[47] to identify
stem-loop structures with a folding free energy of at most
218 kcal/mole (Mfe#218 kcal/mole). For overlapped hairpins,
we only took the one that had the greatest number of paired arm
bases. Forked hairpins were permitted provided that the longest
forked segment contained no more than eight base pairs. For
forked hairpins, we folded the sequence again with the program
RNAshapes [48] and discarded the forked hairpins without stem-
loop optional structure. Only structures that: 1) folded into
hairpins, 2) contained a read in one of the hairpin arm, 3) loop
length of hairpin is less than 20 and minimum pairs of arm is 15, 4)
more than 2 reads located within hairpin, 5) the read sequences
does not span the loop and 6) potential precursors are consistent
with miRNA biogenesis [14,45], were used in further analysis. We
also used a recently discovered property of miRNAs to have lower
folding free energies than random sequences with the same
nucleotide content [31–32]. We thus use z-scores as described by
Washietl et al [33] to filter the candidates. Only hairpins with the
z-score less than 23.0 were novel miRNA genes. Furthermore, the
observation of both a candidate miRNA and a corresponding
candidate miRNA* was defined as high stringency. The sequence
with dominantly abundant reads was named as mature miRNA
and its corresponding complementary sequence as miRNA*.
Target prediction and Gene Ontology (GO) analysis
The conserved targets of known miRNAs and novel miRNAs
were predicted by TargetScan (http://www.targetscan.org/
vert_42/vert_42_data_download/targetscan_41.zip) [35–36]. On-
ly miRNAs with significant over-expression in either C group or P
group were included in target analyses. GO [49] terms and gene
information were downloaded from the NCBI website (ftp://ftp.
ncbi.nih.gov/gene/DATA) on August 2008. The functional
categories scrutinized are biological processes and molecular
functions as defined in the Gene Ontology Consortium database
(http://www.geneontology.org)[49]. Significant overrepresentation
of particular GO terms in the dataset was determined using the
Table 2. The top 6 up-regulated and 14 down-regulated novel miRNAs differentially expressed in patient group (fold changes.2.0
and P-value of ,0.001).
MicroRNA Control reads Patient reads Control percent Patient percent Fold changes P-value
hsa-miR-1943 0 31 0 100 8.15E-17
hsa-miR-1841 0 5 0 100 0.000962473
hsa-miR-1931 0 5 0 100 0.000962473
hsa-miR-1987 0 5 0 100 0.000962473
hsa-miR-1890 8 54 6.392458766 93.60754123 14.64343294 4.51E-20
hsa-miR-1902 3 14 8.989689382 91.01031062 10.12385487 8.25E-06
hsa-miR-1859 103 14 77.22785611 22.77214389 0.294869559 6.11E-07
hsa-miR-1859* 121 14 79.935753 20.064247 0.251004666 5.31E-09
hsa-miR-1947 120 12 82.17333704 17.82666296 0.216939747 6.78E-10
hsa-miR-1971 125 11 83.96961466 16.03038534 0.190906978 4.38E-11
hsa-miR-1866 30 2 87.36474314 12.63525686 0.144626498 0.000498687
hsa-miR-1986 33 2 88.37992777 11.62007223 0.131478635 0.000189704
hsa-miR-1843 43 2 90.83458937 9.16541063 0.100902208 6.98E-06
hsa-miR-1852 62 2 93.45964161 6.540358394 0.069980564 1.05E-08
hsa-miR-1852* 40 1 94.85551703 5.144482971 0.054234937 2.67E-06
hsa-miR-1842 355 4 97.61393329 2.386066705 0.024443915 3.31E-52
hsa-miR-1842* 44 0 100 0 0 4.25E-08
hsa-miR-1834 37 0 100 0 0 5.96E-07
hsa-miR-1971* 34 0 100 0 0 1.85E-06
hsa-miR-1893 18 0 100 0 0 0.000771849
doi:10.1371/journal.pone.0006849.t002
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doi:10.1371/journal.pone.0006849.g005
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Bonferroni-corrected p-values are reported and a cutoff of 0.1 on
the Bonferroni-corrected P value was applied. As described by Lall
et al [51], Bonferroni-corrected P values for overrepresented GO
terms for the targets of each miRNA are plotted on a negative log2
scale (e.g. p-values 2
0=1, 2
26=0.015625). We performed 2-way
hierarchical clustering with the program MeV [52], with the
Pearson correlation coefficient and average linkage clustering.
Quantitative real-time reverse transcription PCR assays
Quantitative real-time RT-PCR (qRT-PCR) was performed as
described[53] and employed a Hairpin-it
TM miRNAs Real-Time
PCR Quantitation Kit containing stem-loop like RT primer,
miRNA specific PCR primers and Molecular Beacon probe
(GenePharma, Shanghai, China). Briefly, RNA was reverse-
transcribed to cDNA with miRNA specific stem-loop like RT
primer and the expression of each miRNA relative to normal
control was determined using the 2
-DDC
T method[54]. Compar-
ative real-time PCR was performed in triplicate. The no-template
real-time PCR was used as negative control in each PCR reaction.
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